Results 81 to 90 of about 1,634 (161)

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source

Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) infections are a leading cause of lower respiratory tract infections (LRTI), particularly bronchiolitis and pneumonia, leading to significant hospitalizations and economic burden in infants. In Colombia, RSV
Maria Carrasquilla-Sotomayor, Nelson J. Alvis-Zakzuk, Wilfrido Coronell-Rodríguez, Andres Arias, Lina Moyano-Tamara, Juan Carlos Alvarado-Gonzalez, Fernando De la Hoz-Restrepo, Nelson Alvis-Guzman   +7 more
doaj   +1 more source

Nirsevimab: a promising therapy for RSV

The Lancet Microbe, 2022
openaire   +1 more source

Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. [PDF]

BMJ Open
Masukume G, McMorrow A, Dawood I, Rafdhy K, O'Brien F, Desmond C, O'Connell D, Murphy B, Ronan E, Purtill H, Philip RK.   +10 more
europepmc   +1 more source

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study. [PDF]

Pediatr Pulmonol
La Regina DP, Spatuzzo M, Bonci E, Nenna R, Petrarca L, Conti MG, Mancino E, Pierangeli A, Antonelli G, Midulla F.   +9 more
europepmc   +1 more source

Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study. [PDF]

Arch Dis Child
Moore T, Afridi A, Aminudin NH, Gibbons C, Grant O, Fucikova H, Moore CM.   +6 more
europepmc   +1 more source

Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis. [PDF]

PLoS One
Gebretekle GB, Lan M, Xi M, Ximenes R, Buchan SA, Abrams EM, Andrew MK, Brousseau N, Killikelly A, Money D, Papenburg J, Rafferty E, Robinson JL, Siu W, Tunis M, Tuite AR.   +15 more
europepmc   +1 more source

Dual Immunization Against RSV With RSVpreF and Nirsevimab.

JAMA Pediatr
Tréluyer L, Bertrand M, Gabet A, Jabagi MJ, Kolla E, Olié V, Zureik M, Rachas A.   +7 more
europepmc   +1 more source

Efficacy and effectiveness of long-acting monoclonal antibodies and vaccines against RSV: a systematic review and meta-analysis of studies from 2018 to 2025. [PDF]

EClinicalMedicine
Du J, Li S, Hung IFN, Wu JT, Leung K.
europepmc   +1 more source

Hypotonia and Lethargy as Potential Adverse Effect to Nirsevimab Administration in a Newborn Infant. [PDF]

J Pediatr Pharmacol Ther
Molina VMV, Mallo MN, Del Río ST, López-Ortego P, Solís-García G.   +4 more
europepmc   +1 more source